ArticleJournal of the American Chemical Society2025
Rabies Virus Targeting NIR-II Phototheranostics.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Exosomes in brain diseases: Mechanisms, advances, and perspectives.Bioactive materials · 2027Review
- Donor-Acceptor Bridging via Twisted Quasi-Double-Bond: A Facile Design Strategy for Typical NIR-II AIEgen with "Simple" Structure.Chemical & biomedical imaging · 2026Article
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- Algae-Integrated Optoelectronic Nanoplatform for Tumor Hypoxia Relief and Enhanced Photodynamic Therapy.Advanced healthcare materials · 2026Article
- NIR-II photothermal-driven pulsatile PTH release for osteoporotic bone repair.National science review · 2026Article
- Unimolecular dual-reporter probes for early kidney injury diagnosis through synchronousNational science review · 2026Article
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- Photothermally-activated nano-delivery system for on-demand treatment of diabetic wound infections.International journal of pharmaceutics: X · 2026Article
- Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue repair.Materials today. Bio · 2026Review
- Surface modification and nanodelivery of hypocrellin-based photosensitizers: photophysical optimization and biomedical applications.Journal of nanobiotechnology · 2026Review
- Molecularly sculpted NIR-II nano-igniter converts local photothermal heat into systemic antitumor vaccination.Journal of nanobiotechnology · 2026Article
- From nanotechnology to immunomodulation: emerging strategies targeting macrophages in high altitude pulmonary hypertension.Journal of nanobiotechnology · 2026Review
- Advances and Opportunities in NIR-II Endoscopy: From Diagnosis to Therapeutic Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications.Bioactive materials · 2026Review
- Enhancing photothermal therapy effectiveness via tartrazine-induced optical clearing of biological tissues.Scientific reports · 2026Article
- NIR imaging-guided carbon monoxide nanomedicine: Design strategies, stimuli-responsive release, and multimodal synergistic therapies for precision disease treatment.Materials today. Bio · 2026Review
- Tailoring Advanced Metal-Based Nanomedicines for Adaptable Nanodynamic Disease Therapies and Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Photo-responsive nanozymes: from photocatalytic mechanisms to precision therapy.Frontiers in chemistry · 2026Review
- "Dual-Boosting" Strategy to Enhance Radical Generation of Photosensitizer for Mitochondria-Targeted Phototherapy.Research (Washington, D.C.) · 2026Article
- Strategies for biofilm inhibition: the role of synthetic drug- and nanotechnology-based agents.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies is a viral disease with an almost 100% fatality rate, primarily transmitted through bites from infected animals, with a long incubation period and no effective clinical treatments to date. Herein, we developed the first fluorescent nanotheranostic probe in the second near-infrared (NIR-II) window capable of efficiently crossing the blood-brain barrier (BBB), precisely targeting rabies virus (RABV), and enabling safe photodynamic therapy (PDT). This probe is based on a novel NIR-II organic polyacetylene fluorophore, DK, which self-assembles via a click reaction with a nanoparticle carrier, N3-PEG2000-R, that we synthesized with a high biocompatibility and BBB permeability. The probe surface is further modified with an aptamer that specifically binds to RABV glycoprotein (RVG), resulting in our final nanotheranostic probe,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.